Daily Brief United States: Unity Software, Exxon Mobil, Tether, Netgear Inc, OpGen and more

• Founded in 2022, Unity Software Shanghai Co. (Unity 3D/Unity China) is a Chinese company that provides a 3D development platform, and AR/VR solutions to the gaming industry.
• The company is a subsidiary of Unity Software (U US) and focuses on localisation Unity’s products and services to the Chinese market.
• The company was valued at around US$1bn at the time of its formation and based on deal terms, might go for a listing when its valuation hits US$3.6bn.

• Exxon Mobil is about to report its Q1 2023 results, investors should keep their long-term view and dismiss any quarterly noise.
• Management is now becoming increasingly aggressive in its expansion efforts and should provide more information on that during the quarter.
• If you bought Exxon Mobil Corporation (NYSE:XOM) back in 2020 when I laid out my investment thesis on the company, then most likely you wouldn’t be bothered by the quarterly fluctuations of the stock.

• The best design often goes unnoticed. DeFi lending and borrowing stalwarts Aave and Compound have proven themselves to be great design: critical for day-to-day functioning but largely taken for granted.
• This becomes apparent when a competitor experiences an exploit, highlighting the reliability of Aave and Compound
• When last we checked in on these protocols in December they were in a period of change.

• NTGR reported first quarter results asserting sell through was healthy but channel partners were not replenishing their inventory
• Heading into the results, we had cited the lack of deep discounts in the quarter as a sign that inventory had stabilized. 
• NTGR is entering the second quarter with no expectation of channel partners coming back with increased order flow

OpGen has announced that Curetis (its German subsidiary) has successfully met the remaining key milestones for Unyvero A30 RQ under the initial R&D collaboration with FIND (a global non-profit alliance for diagnostics), triggering a $0.3m milestone payment to OpGen. This development follows the achievement of certain other key milestones in January 2023. While OpGen is still working on the next set of deliverables under the expanded scope of R&D agreement (April 2023), the successful completion of the feasibility phase indicates Unyvero’s potential adaptability for low- and middle-income countries (LMICs). As a step forward, OpGen will seek to expand the agreement towards clinical studies and subsequent commercialization.